35results about How to "Aid in early diagnosis" patented technology

The invention provides a nano-fluorescent probe targeting pancreatic cancer circulating tumor cells. The probe comprises H2O2 responsive fluorescent small molecules and polymers targeting pancreatic cancer surface markers, and the H2O2 responsive fluorescent small molecules and the polymers targeting the pancreatic cancer surface markers have opposite hydrophilicity and hydrophobicity. Through thehigh expression of CD44 antigen specificity binding of hyaluronic acid and the pancreatic cancer tumor surface, the HA-NP-BE nano-fluorescent probe can tragetingly enter pancreatic cancer cells to detect H2O2 in the cells and image H2O2, rapid responsiveness is achieved, the pancreatic cancer tumor cells and normal cells can be effectively distinguished, CTC in pancreatic cancer tumor patients isdetected, and early disgnosis of pancreatic cancer is facilitated.

The invention provides a method for identifying a human growth hormone protein existence form biomarker spectrum, which comprises the following steps: collecting human growth hormone secreting pituitary adenoma and normal pituitary tissue samples, respectively extracting tissue proteins, carrying out two-way gel electrophoresis, western blot and coomassie brilliant blue staining, scanning a visual PVDF membrane and a two-way gel into a digital image, digesting corresponding two-way gel protein spots with trypsin, purifying, and identifying a GHP biomarker spectrum through mass spectrum identification and bioinformatics analysis; and identifying post-translational modifications and shear variations on GHP by using quantitative phosphorylated proteomics, ubiquitinated proteomics, and acetylated proteomics analysis in combination with bioinformatics. According to the invention, the GHP change mode between the growth hormone secreting pituitary adenoma and normal pituitary tissues can be identified, 46 kinds of GHPs are identified in the growth hormone secreting pituitary adenoma, 35 kinds of GHPs are identified in the normal pituitary tissues, and 11 kinds of GHPs only appear in the growth hormone secreting pituitary adenoma tissues.

The invention discloses primers and a probe for detecting relative expression quantity of CDX2 gene and a detection method. The forward and reverse primers for amplification coverage of CDX2 gene and the probe are respectively CDX2-F, CDX2-R and CDX2-Probe. The forward and reverse primers and the probe for detecting reference gene Abl are respectively Abl-F, Abl-R and Abl-Probe. The detection reagent and the method have high precision, and results are convenient to read and discriminate. In addition, specificity is good, sensitivity is high, and operation is simple. The invention is helpful for clinical early diagnosis of leukemia and monitoring of minimal residual disease (MRD), and is of great significance for timely intervention of treatment, adjustment of therapeutic schedule, evaluation of treatment effect, prediction of prognosis and prevention of clinical relapse.

The present invention relates to a monoclonal antibody that recognizes monohydric phenol compounds. The nucleic acid sequence information of the heavy chain coding region is encoded by the DNA sequence shown in SEQ 1; the amino acid sequence information of the heavy chain coding region is the amino acid shown in SEQ 2 Sequence coding; the nucleic acid sequence information of the light chain coding region is coded by the DNA sequence shown in SEQ 9; the amino acid sequence information of the light chain coding region is coded by the amino acid sequence shown in SEQ 10. The monoclonal antibody for recognizing monohydric phenolic compounds described in the present invention can detect monohydric phenolic compounds in human body fluids, and the content of monohydric phenolic compounds can reflect the degree of cell activity in the body of the subject and the immunity of the body state, thus contributing to the early diagnosis of tumors. The monoclonal antibody for recognizing monohydric phenolic compounds of the present invention can effectively detect gastric cancer, colon cancer, rectal cancer, esophageal cancer, pancreatic cancer and other digestive tract tumors.

The present invention is a construction method and application of neuroimaging marker morphological fusion classification index. The construction method includes the following contents: obtaining structural MRI data of M centers, extracting brain structural image characteristic data; performing independent training with the data of each center, respectively Establish the classification model of each center and obtain the classification model of M centers; for any sample, in the classification model of all centers, calculate the classification weight value of the sample in each feature of each model, that is, the SHAP matrix; then use each The sample size used in the training of each model is the weight, and a single morphological fusion classification index MICI value is obtained by calculating according to formula (1): where Si represents the sample size of model i, B represents the total number of features, and a i Represents the SHAP value of feature a in model i, i=1~M. The MICI value can well realize the discrimination between patients with mental illness and normal people, and has good interpretability, evolution and scalability.